Edgewise Therapeutics, Inc. (EWTX) Price Target Raised to $59 on Positive HCM Trial Data

We recently compiled a list of the 10 Best Healthcare Stocks to Buy According to Wall Street Analysts. Edgewise Therapeutics, Inc. (NASDAQ:EWTX) is among the best healthcare stocks.

TheFly reported on June 17 that RBC Capital increased its price target for EWTX to $59 from $48 while maintaining an Outperform rating on the shares. The firm highlighted the company’s 12-week results from the ‘7500 HCM trial, noting that the data demonstrated encouraging safety and efficacy outcomes. RBC Capital believes the findings could support a future Phase 3 trial design without the need for titration echocardiograms, potentially improving the therapy’s usability in real-world settings. The firm also emphasized EWTX’s broader cardiology opportunity, citing the potential of ‘7500 and the company’s pipeline to support significant long-term growth.

Earlier this month, on June 1, Edgewise Therapeutics, Inc. (NASDAQ:EWTX) announced a definitive agreement with Servier for the acquisition of sevasemten and its muscular dystrophy business for $1.55 billion in upfront cash and up to $1.1 billion in additional milestone payments, representing potential total consideration of $2.65 billion. The transaction strengthens EWTX’s financial position and allows the company to focus its strategy on advancing its cardiovascular pipeline. Following the deal, Edgewise will shift into a cardiovascular-focused company, with programs including EDG-7500 for hypertrophic cardiomyopathy, EDG-15400 for HFpEF, and EDG-003. The company plans to continue progressing its cardiovascular development programs using the enhanced financial flexibility.

Edgewise Therapeutics, Inc. (NASDAQ:EWTX) is a clinical-stage biopharmaceutical company developing precision oral medicines for severe muscle diseases, using a unique approach focused on protecting skeletal and cardiac muscles from damage.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years 

Disclosure: None. Follow Insider Monkey on Google News.